8-K
filed November 6, 2024, 6:59 PM ET
CIK 0001061027
other material
confidence high
sentiment negative
materiality 0.75
Viracta Therapeutics, Inc.: restructuring charge — Viracta cuts 42% of staff, reduces board to 6; focuses on Nana-val PTCL program
Viracta Therapeutics, Inc.
- Workforce reduction of ~42% to conserve resources for Nana-val development; expects $0.7M in severance costs.
- Four directors (Barlow, Chung, Murphy, Rubino) resigned Oct 31; board size reduced from 10 to 6 seats.
- Company prioritizing Nana-val for R/R EBV-positive PTCL toward potential NDA submission.
- Actions intended to reduce cash burn and streamline operations; remaining board includes Chairman Pomerantz.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jane F. Barlow resigned as Director at Viracta Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Stephen Rubino resigned as Director at Viracta Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Sam Murphy resigned as Director at Viracta Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jane Chung resigned as Director at Viracta Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.95
Viracta Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force affecting Workforce reduction affecting approximately 42% of the Company's workforce (approximately 42% of the Company's workforce).
- Type
- restructuring
- Charge
- approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force
- Affected area
- Workforce reduction affecting approximately 42% of the Company's workforce
- Headcount
- approximately 42% of the Company's workforce
Exact text from the filing
On October 31, 2024, Viracta Therapeutics, Inc. (the “Company”), committed to and implemented a reduction in force that impacted approximately 42% of the Company’s workforce. The Company expects to recognize approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force, consisting primarily of severance payments and related benefits.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.